AI: The Marriage of High Tech & Big Pharma
By

By
Novo Nordisk is the latest pharmaceutical major to partner directly with a high-tech giant to advance AI in their operations, including for drug development, manufacturing, and the supply chain. A roundup of the latest partnerships and projects.

Mastering the Supply Chain, Digitalization & Global Shifts
By

By
An upcoming DCAT conference, The DCAT Global Summit 2026: The Future of Bio/Pharma: Mastering the Supply Chain, Digitalization & Global Shifts, June 10-11, in Sitges, Barcelona, Spain, will provide executive perspectives on AI and digital transformation across the bio/pharmaceutical value chain.

CEOs, Senior Executives Highlight Expansions at the DCAT Member Company Announcement Forum
By

By
CEOs and senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week.

DCAT Value Chain Insights Bonus Coverage: From DCAT Week 2026 Member Company News Roundup 
By

By
What other DCAT Member Companies are making news from DCAT Week? A roundup of the latest developments from suppliers and CDMOs/CMOs.

DCAT Week in Review: A Snapshot View of DCAT’s Education Programs
By

By
The education programs at DCAT Week 2026, held March 23–26, in New York, featured senior executives and thought leaders providing perspectives on key issues impactful to the business of bio/pharma development and manufacturing and the pharma customer–supplier relationship.

Oral Obesity Drug Battle Is On with FDA OK for Lilly’s Orforglipron
By

By
Lilly is entering the oral obesity drug market by gaining FDA approval for Foundayo (orforglipron), a small-molecule (non-peptide) oral GLP-1 receptor agonist, setting up head-on competition with an oral version of Novo Nordisk’s obesity drug, Wegovy (semaglutide).

What is Top of the Industry’s Sustainability Agenda in 2026?
By

By
Decarbonizing, standardized reporting of value-chain emissions, and coalescing talent and technology are high on the industry’s sustainability agenda in 2026.

Change, Change, & Change: The Pharma Industry’s Outlook & Response
By

By
The bio/pharma industry faces geopolitical uncertainties, fluid trade conditions, and greater product and supply-chain complexity. What lies ahead for bio/pharma companies and suppliers? An outlook for the industry. 

Future-Proofing the Pharma Customer & Supplier Relationship
By

By
The US Supreme Court ruling on reciprocal tariffs is the latest turn in a fluid global trade situation. How can pharma companies and their suppliers adapt? An executive panel at DCAT Week will share ways on how they are collaborating.

AI: The State of the State in Supply Management 
By

By
AI and digitalization hold great potential in transforming business functions, but where do they really stand in supply management? An executive panel at DCAT Week will share their perspectives on how AI may transform how pharma companies and their suppliers do business.